Revenue increased 24.17% to $5.1 million in 2025 compared to $4.1 million in 2024. Net loss widened to $7.8 million in 2025 from $5.6 million in 2024. The company operates a vertically integrated regenerative medicine model including education (ISSCA), manufacturing (Cellgenic), and clinical services. Working capital deficit stands at $35.6 million as of December 31, 2025. The company is currently in default on $1.16 million of unsecured promissory notes.